Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers

Activating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions are potent drivers of oncogenesis. The recent FDA approvals of highly potent and selective RET inhibitors, selpercatinib and pralsetinib, has altered the therapeutic management of RET aberrant tumors. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Adashek, Jacob J., Desai, Aakash P., Andreev-Drakhlin, Alexander Y., Roszik, Jason, Cote, Gilbert J., Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492504/
https://www.ncbi.nlm.nih.gov/pubmed/34493590
http://dx.doi.org/10.1158/1535-7163.MCT-21-0329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492504/
https://www.ncbi.nlm.nih.gov/pubmed/34493590
http://dx.doi.org/10.1158/1535-7163.MCT-21-0329

Ejemplares similares